Objective: To analyze the short-term (3 weeks) adverse respiratory events after
bronchial thermoplasty(BT) in patients with severe
asthma. Methods: The China-Japan Friendship Hospital recruited 62 patients with severe
asthma for BT treatment from March 2014 to July 2016, with a total of 183 BT procedures. The data of adverse respiratory events within 3 weeks after procedure were collected to analyze the factors that might potentially influence the occurrence of adverse events. Results: Forty-three patients (69.4%) experienced adverse respiratory events within 3 weeks
after treatment. Totally 153 adverse respiratory events occurred after 87 procedures(47.5%). The main adverse events were
cough (15 events, 8.20%), sputum production (37 events, 20.22%), temporary PEF reduction (37 events, 20.22%), chest distress (12 events, 6.56%), blood in sputum (11 events, 6.01%),
asthma exacerbation (10 events, 5.46%), and
pneumonia(6 events, 3.28%). Most events were relieved or resolved with standard
therapy in 1 week. No severe adverse events including tracheal intubation, malignant arrhythmias or death occurred within 3 weeks after procedure. The baseline eosinophil percentage in induced sputum and blood, operation times, and preoperative FEV(1) (% predicted) might influence the occurrence of adverse events
after treatment. Patients with preoperative FEV(1) (% predicted) ≥60% had lower risk of adverse events. Conclusion: BT showed a good security profile in treating patients with severe
asthma within 3 weeks after procedure.